A Multicenter Randomized Double-Blind Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Crohn’s Disease
-
Age: Between 18 - 80 Years
-
Gender: Male or Female
-
Other Inclusion Criteria:
- Subjects who have completed Study M16-006 or Study M15-991 and have achieved clinical response
You may not be eligible for this study if the following are true:
-
- Subject is considered by the Investigator, for any reason, to be an unsuitable candidate for the study
- Subject who has a known hypersensitivity to risankizumab or the excipients of any of the study drugs or the ingredients of CHO, or had an AE during Studies M16 006 or M15-991 that in the Investigator's judgment makes the subject unsuitable for this study
- Subject is not in compliance with prior and concomitant medication requirements throughout Studies M16-006 or M15-991
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.